Michael W Deininger (Michael Deninger, Michael Deininger, Michael E Deininger)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 42

Top Topics

Peritoneal Dialysis

Newly Diagnosed

Tyrosine Kinase

Top Venues

Nature medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Jorge E Cortes, Koiji Sasaki, Dong-Wook Kim, Timothy P Hughes, Gabriel Etienne, Michael J Mauro, Andreas Hochhaus, Fabian Lang, Michael C Heinrich, Massimo Breccia, Michael W Deininger, Yeow Tee Goh, Jeroen J W M Janssen, Moshe Talpaz, Valle Gomez Garcia de Soria, Philipp le Coutre, Daniel J DeAngelo, Andrea Damon, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Delphine Rea
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia 38 (7) (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia (2024)
Jorge E Cortes, Koiji Sasaki, Dong-Wook Kim, Timothy P Hughes, Gabriel Etienne, Michael J Mauro, Andreas Hochhaus, Fabian Lang, Michael C Heinrich, Massimo Breccia, Michael W Deininger, Yeow Tee Goh, Jeroen J W M Janssen, Moshe Talpaz, Valle Gomez Garcia de Soria, Philipp le Coutre, Daniel J DeAngelo, Andrea Damon, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Delphine Rea
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia 38 (7) (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38 (3) (2024)
Jorge E Cortes, Koiji Sasaki, Dong-Wook Kim, Timothy P Hughes, Gabriel Etienne, Michael J Mauro, Andreas Hochhaus, Fabian Lang, Michael C Heinrich, Massimo Breccia, Michael W Deininger, Yeow Tee Goh, Jeroen J W M Janssen, Moshe Talpaz, Valle Gomez Garcia de Soria, Philipp le Coutre, Daniel J DeAngelo, Andrea Damon, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Delphine Rea
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia 38 (7) (2024)
Fieke W Hoff, William Blum, Ying Huang, Rina Li Welkie, Ronan Swords, Jennifer Dunlap, Eytan M Stein, Tara L Lin, Kellie J Archer, Prapti A Patel, Robert H Collins, Maria R Baer, Vu H Duong, Martha L Arellano, Wendy Stock, Olatoyosi Odenike, Robert L Redner, Tibor J Kovacsovics, Michael W Deininger, Joshua F Zeidner, Rebecca L Olin, Catherine C Smith, James M Foran, Gary J Schiller, Emily Curran, Kristin L Koenig, Nyla A Heerema, Timothy L Chen, Molly Martycz, Mona Stefanos, Leonard Rosenberg, Brian J Druker, Ross L Levine, Amy Burd, Ashley O Yocum, Uma Borate, Alice S Mims, John C Byrd, Yazan F Madanat
Beat-AML 2024 ELN-Refined Risk Stratification for Older Adults with Newly Diagnosed AML Given Lower-Intensity Therapy. Blood advances (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38 (3) (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38 (3) (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38 (3) (2024)
Jorge E Cortes, Koiji Sasaki, Dong-Wook Kim, Timothy P Hughes, Gabriel Etienne, Michael J Mauro, Andreas Hochhaus, Fabian Lang, Michael C Heinrich, Massimo Breccia, Michael W Deininger, Yeow Tee Goh, Jeroen J W M Janssen, Moshe Talpaz, Valle Gomez Garcia de Soria, Philipp le Coutre, Daniel J DeAngelo, Andrea Damon, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Delphine Rea
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia (2024)
Nataly Cruz-Rodriguez, Hua Tang, Benjamin Bateman, Weiping Tang, Michael W Deininger
BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph + leukemias? Leukemia (2024)
Nataly Cruz-Rodriguez, Hua Tang, Benjamin Bateman, Weiping Tang, Michael W Deininger
BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph + leukemias? Leukemia 38 (9) (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38 (3) (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38 (3) (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38 (3) (2024)
Jorge E Cortes, Koiji Sasaki, Dong-Wook Kim, Timothy P Hughes, Gabriel Etienne, Michael J Mauro, Andreas Hochhaus, Fabian Lang, Michael C Heinrich, Massimo Breccia, Michael W Deininger, Yeow Tee Goh, Jeroen J W M Janssen, Moshe Talpaz, Valle Gomez Garcia de Soria, Philipp le Coutre, Daniel J DeAngelo, Andrea Damon, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Delphine Rea
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia 38 (7) (2024)
Elias J Jabbour, Jane F Apperley, Jorge E Cortes, Delphine Rea, Michael W Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton, Michael J Mauro, Franck Nicolini, Javier Pinilla-Ibarz, Gianantonio Rosti, Philippe Rousselot, Neil P Shah, Moshe Talpaz, Alexander Vorog, Xiaowei Ren, Hagop M Kantarjian
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia (2024)
Meenu Kesarwani, Zachary Kincaid, Mohammad Azhar, Jacob Menke, Joshua Schwieterman, Sekhu Ansari, Angela Reaves, Michael W Deininger, Ross L Levine, H Leighton Grimes, Mohammad Azam
MAPK-negative feedback regulation confers dependence to JAK2 V617F signaling. Leukemia (2023)
Ho-Jae Han, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Shinya Kimura, Michael W Deininger, Jong Won Kim, Dennis Dong Hwan Kim
In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile. Leukemia 38 (2) (2023)
Ho-Jae Han, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Shinya Kimura, Michael W Deininger, Jong Won Kim, Dennis Dong Hwan Kim
In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile. Leukemia 38 (2) (2023)
Helong Gary Zhao, Michael W Deininger
ALWAYS STRESSED BUT NEVER EXHAUSTED: HOW STEM CELLS IN MYELOID NEOPLASMS AVOID EXTINCTION IN INFLAMMATORY CONDITIONS. Blood (2023)
Ho-Jae Han, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Shinya Kimura, Michael W Deininger, Jong Won Kim, Dennis Dong Hwan Kim
In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile. Leukemia 38 (2) (2023)
Ho-Jae Han, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Shinya Kimura, Michael W Deininger, Jong Won Kim, Dennis Dong Hwan Kim
In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile. Leukemia 38 (2) (2023)
Jonathan E Constance, Mary M McFarland, Tallie Casucci, Michael W Deininger, Elena Y Enioutina, Kathleen M Job, Richard S Lemons, Carol S Lim, Robert M Ward, Venkata Kashyap Yellepeddi, Kevin M Watt
Mapping the Evidence for Opioid-Mediated Changes in Malignancy and Chemotherapeutic Efficacy: Protocol for a Scoping Review. JMIR research protocols 12 (2023)
May Garrett, Beverly Knight, Jorge E Cortes, Michael W Deininger
Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia. Cancer medicine (2023)
Ho-Jae Han, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Shinya Kimura, Michael W Deininger, Jong Won Kim, Dennis Dong Hwan Kim
In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile. Leukemia (2023)
Jonathan E Constance, Mary M McFarland, Tallie Casucci, Michael W Deininger, Elena Y Enioutina, Kathleen M Job, Richard S Lemons, Carol S Lim, Robert M Ward, Venkata Kashyap Yellepeddi, Kevin M Watt
Mapping the Evidence for Opioid-Mediated Changes in Malignancy and Chemotherapeutic Efficacy: Protocol for a Scoping Review. JMIR research protocols 12 (2023)
Ho-Jae Han, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Shinya Kimura, Michael W Deininger, Jong Won Kim, Dennis Dong Hwan Kim
In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile. Leukemia 38 (2) (2023)
Nicholas C P Cross, Thomas Ernst, Susan Branford, Jean-Michel Cayuela, Michael W Deininger, Alice Fabarius, Dennis Dong Hwan Kim, Katerina Machova Polakova, Jerald P Radich, Rüdiger Hehlmann, Andreas Hochhaus, Jane F Apperley, Simona Soverini
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia (2023)
Ellin Berman, Neil P Shah, Michael W Deininger, Jessica K Altman, Maria Amaya, Kebede H Begna, Ravi Bhatia, Onyee Chan, Robert H Collins, Peter Curtin, Daniel J DeAngelo, Michael W Drazer, Lori Maness, Leland L Metheny, Sanjay Mohan, Joseph Moore, Vivian Oehler, Keith W Pratz, Iskra Pusic, Michal Rose, William Shomali, B Douglas Smith, Michael Styler, Kendra Sweet, Moshe Talpaz, Tiffany Tanaka, Srinivas Tantravahi, Steven Tsai, Jennifer Vaughn, Jeanna Welborn, David Yang, Michael Mauro, Jorge E Cortes, Jerald Radich, Brian J Druker
CML and the WHO: Why? Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Antoine N Saliba, Scott H Kaufmann, Eytan M Stein, Prapti Arvind Patel, Maria R Baer, Wendy Stock, Michael W Deininger, William Blum, Gary J Schiller, Rebecca L Olin, Mark R Litzow, Tara L Lin, Brian John Ball, Michael Boyiadzis, Jennifer Dunlap, Olatoyosi Odenike, Martha L Arellano, Alison R Walker, Vu H Duong, Tibor J Kovacsovics, Robert H Collins, Abigail B Shoben, Nyla A Heerema, Matthew C Foster, Kevin L Peterson, Paula A Schneider, Molly Martycz, Theophilus Gana, Leonard Rosenberg, Sonja Marcus, Ashley O Yocum, Timothy L Chen, Mona Stefanos, Alice S Mims, Uma Borate, Amy Burd, Brian J Druker, Ross L Levine, John C Byrd, James M Foran
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Blood advances (2022)
Andreas Reiter, Juliana Schwaab, Daniel J DeAngelo, Jason Gotlib, Michael W Deininger, Kristen M Pettit, Iván Alvarez-Twose, Alessandro Maria Maria Vannucchi, Jens Peter Panse, Uwe Platzbecker, Olivier Hermine, Ingunn Dybedal, Hui-Min Lin, Svetlana N Rylova, Katrin Ehlert, Saša Dimitrijević, Deepti H Radia
Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. Blood advances 6 (21) (2022)
Helong Gary Zhao, Michael W Deininger
CSF3R and SETBP1 getting high on LSD1. Blood 140 (6) (2022)
Gregor Eisenwort, Irina Sadovnik, Alexandra Keller, Daniel Ivanov, Barbara Peter, Daniela Berger, Gabriele Stefanzl, Karin Bauer, Katharina Slavnitsch, Georg Greiner, Karoline V Gleixner, Wolfgang R Sperr, Michael Willmann, Heinz Sill, Peter Bettelheim, Klaus Geissler, Michael W Deininger, Thomas Rülicke, Peter Valent
Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia. Leukemia 35 (11) (2021)
Helong Zhao, Anthony D Pomicter, Anna M Eiring, Anca Franzini, Jonathan Ahmann, Jae-Yeon Hwang, Anna V Senina, Bret Helton, Siddharth M Iyer, Dongqing Yan, Jamshid S Khorashad, Matthew S Zabriskie, Anupriya Agarwal, Hannah M Redwine, Amber D Bowler, Phillip M Clair, Shannon K McWeeney, Brian J Druker, Jeffrey W Tyner, Derek L Stirewalt, Vivian G Oehler, Sooryanarayana Varambally, Kristofer C Berrett, Jeffrey M Vahrenkamp, Jason Gertz, Katherine E Varley, Jerald Radich, Michael W Deininger
MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia by Enhancing Common β Chain Cytokine Receptor Endocytosis. Blood (2021)
Jason Gotlib, Andreas Reiter, Deepti H Radia, Michael W Deininger, Tracy I George, Jens Panse, Alessandro M Vannucchi, Uwe Platzbecker, Iván Alvarez-Twose, Andrzej Mital, Olivier Hermine, Ingunn Dybedal, Elizabeth O Hexner, Lisa K Hicks, Lambert Span, Ruben Mesa, Prithviraj Bose, Kristen M Pettit, Mark L Heaney, Stephen T Oh, Jayita Sen, Hui-Min Lin, Brenton G Mar, Daniel J DeAngelo
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nature medicine (2021)
Daniel J DeAngelo, Deepti H Radia, Tracy I George, William A Robinson, Albert T Quiery, Mark W Drummond, Prithviraj Bose, Elizabeth O Hexner, Elliott F Winton, Hans-Peter Horny, Meera Tugnait, Oleg Schmidt-Kittler, Erica K Evans, Hui-Min Lin, Brenton G Mar, Srdan Verstovsek, Michael W Deininger, Jason Gotlib
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nature medicine (2021)
Helong Zhao, Michael W Deininger
Declaration of Bcr-Abl1 independence. Leukemia 34 (11) (2020)
Ami B Patel, Anthony D Pomicter, Dongqing Yan, Anna M Eiring, Orlando Antelope, Jonathan A Schumacher, Todd W Kelley, Srinivas K Tantravahi, Tibor J Kovacsovics, Paul J Shami, Thomas O'Hare, Michael W Deininger
Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. Leukemia 34 (11) (2020)
Hein Than, Anthony D Pomicter, Dongqing Yan, Larry P Beaver, Anna M Eiring, William L Heaton, Anna Senina, Phillip M Clair, Sharon Shacham, Clinton C Mason, Thomas O' Hare, Michael W Deininger
Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells. Leukemia 34 (6) (2020)
Amy Burd, Ross L Levine, Amy S Ruppert, Alice S Mims, Uma Borate, Eytan M Stein, Prapti Patel, Maria R Baer, Wendy Stock, Michael W Deininger, William Blum, Gary Schiller, Rebecca Olin, Mark Litzow, James Foran, Tara L Lin, Brian Ball, Michael Boyiadzis, Elie Traer, Olatoyosi Odenike, Martha Arellano, Alison Walker, Vu H Duong, Tibor Kovacsovics, Robert H Collins, Abigail B Shoben, Nyla A Heerema, Matthew C Foster, Jo-Anne Vergilio, Tim Brennan, Christine Vietz, Eric Severson, Molly Miller, Leonard Rosenberg, Sonja Marcus, Ashley Yocum, Timothy Chen, Mona Stefanos, Brian J Druker, John C Byrd
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nature medicine 26 (12) (2020)
Helong Zhao, Michelle Mendenhall, Michael W Deininger
Imatinib is not a potent anti-SARS-CoV-2 drug. Leukemia 34 (11) (2020)